Takeda Pharmaceutical Company Limited vs MorphoSys AG: A Gross Profit Performance Breakdown

Takeda vs. MorphoSys: A Decade of Profit Dynamics

__timestampMorphoSys AGTakeda Pharmaceutical Company Limited
Wednesday, January 1, 2014639009781256834000000
Thursday, January 1, 20151061458971271973000000
Friday, January 1, 2016496465151173296000000
Sunday, January 1, 2017667578401274610000000
Monday, January 1, 2018746458761437534000000
Tuesday, January 1, 2019596701052201424000000
Wednesday, January 1, 20203185243192203504000000
Friday, January 1, 20211474000002462160000000
Saturday, January 1, 20222296470032783406000000
Sunday, January 1, 20231799233132832257000000
Monday, January 1, 20242832257000000
Loading chart...

Unlocking the unknown

A Tale of Two Giants: Takeda vs. MorphoSys

In the ever-evolving pharmaceutical landscape, Takeda Pharmaceutical Company Limited and MorphoSys AG stand as titans, each with a unique trajectory in gross profit performance. From 2014 to 2023, Takeda's gross profit surged by approximately 125%, peaking at a staggering 2.83 trillion in 2023. This growth underscores Takeda's strategic prowess in expanding its global footprint and diversifying its product portfolio.

Conversely, MorphoSys AG, a smaller yet formidable player, experienced a more volatile journey. Its gross profit saw a remarkable 500% increase from 2014 to 2020, reaching its zenith in 2020. However, subsequent years showed fluctuations, highlighting the challenges faced by biotech firms in maintaining consistent growth.

This comparative analysis not only showcases the financial health of these companies but also reflects broader industry trends, offering valuable insights for investors and stakeholders alike.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025